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Abstract
Background: Bone is the most common site of breast cancer distant metastasis, affecting 50–70 % of patients who
develop metastatic disease. Despite decades of informative research, the effective prevention, prediction and
treatment of these lesions remains elusive. The Breast Cancer to Bone (B2B) Metastases Research Program consists
of a prospective cohort of incident breast cancer patients and four sub-projects that are investigating priority areas
in breast cancer bone metastases. These include the impact of lifestyle factors and inflammation on risk of bone
metastases, the gene expression features of the primary tumour, the potential role for metabolomics in early detection
of bone metastatic disease and the signalling pathways that drive the metastatic lesions in the bone.
Methods/Design: The B2B Research Program is enrolling a prospective cohort of 600 newly diagnosed, incident, stage
I-IIIc breast cancer survivors in Alberta, Canada over a five year period. At baseline, pre-treatment/surgery blood samples
are collected and detailed epidemiologic data is collected by in-person interview and self-administered questionnaires.
Additional self-administered questionnaires and blood samples are completed at specified follow-up intervals (24, 48
and 72 months). Vital status is obtained prior to each follow-up through record linkages with the Alberta Cancer
Registry. Recurrences are identified through medical chart abstractions. Each of the four projects applies specific
methods and analyses to assess the impact of serum vitamin D and cytokine concentrations, tumour transcript and
protein expression, serum metabolomic profiles and in vitro cell signalling on breast cancer bone metastases.
Discussion: The B2B Research Program will address key issues in breast cancer bone metastases including the
association between lifestyle factors (particularly a comprehensive assessment of vitamin D status) inflammation and
bone metastases, the significance or primary tumour gene expression in tissue tropism, the potential of metabolomic
profiles for risk assessment and early detection and the signalling pathways controlling the metastatic tumour
microenvironment. There is substantial synergy between the four projects and it is hoped that this integrated program
of research will advance our understanding of key aspects of bone metastases from breast cancer to improve the
prevention, prediction, detection, and treatment of these lesions.
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Background
Breast cancer is the most common cancer in women in
North America with over 250,000 cases annually and
approximately 45,000 deaths [1, 2]. In patients who de-
velop metastatic disease, 50–70 % will have bone in-
volvement [3–6] and the propensity for primary breast
cancer to metastasize to bone has been recognised for
over one hundred years since the time of Paget’s specu-
lation on the relative roles of “seed and soil” in the pro-
gression of cancer [7, 8]. Approximately 10 % of all
breast cancer patients, without evidence of bone me-
tastases at the time of diagnosis, will have a first
relapse in bone within five years of their primary diag-
nosis [3, 9, 10]. Although women with predominant or
exclusive bone involvement typically live longer than
women with other sites of breast cancer metastasis,
these lesions cause serious lingering morbidity as a re-
sult of pathologic bone fractures, bone pain, hypercal-
cemia and spinal cord compression, and eventually
culminate in death [6, 11].
Occult micrometastases have been detected in bone
stromal aspirates from over 50 % of women at the time
of primary breast cancer diagnosis [12–15]. However,
there is no current method to identify the features of
micrometastases that will eventually progress to create a
clinically detectable and symptomatic bone lesion; some
may remain dormant indefinitely. Two decades of re-
search have revealed that bone metastasis is a multi-step
process of adhesion, invasion, angiogenesis and osteoly-
sis, but the successful prevention, prediction and treat-
ment of these lesions remains elusive. New therapeutic
strategies for bone metastases have become available re-
cently [16], however current treatment options are gen-
erally palliative.
Bone metastases from breast cancer are predominantly
osteolytic although osteosclerotic and mixed lesions can
be observed in the same patient [17, 18]. Osteolytic le-
sions are dominated by osteoclasts that mediate bone re-
sorption during the normal process of bone remodelling
[19]. The presence of metastatic breast cancer cells in
the bone drives complex interactions between the breast
cancer cells, the bone and stromal cells resulting in the
recruitment of osteoclast precursors, osteoclast activa-
tion and establishment of symptomatic lytic metastases
[20–24]. The bone matrix is a reservoir for growth fac-
tors that are released during breast cancer induced bone
lysis; these growth factors enhance the recruitment and
proliferation of osteoclast progenitors and breast cancer
cells. This “vicious cycle” involving recruitment of stro-
mal growth factors, activation of osteoclasts, and further
proteolysis drives the progressive osteolysis observed in
primary breast carcinoma metastasis to bone [25, 26]
and is a central target for disruption by current anti-
metastatic treatment strategies [27].
The advent of powerful gene profiling technologies
has enabled rapid advances in our understanding of the
biological basis of bone tropism in subsets of metastatic
breast cancer [28–30] and suggested that breast cancer
cell recruitment to metastatic sites is attributable to the
activation of specific molecular programs in the primary
tumour [31–33]. However, despite almost a decade of
subsequent research, no primary tumour gene expres-
sion signatures have yet been independently validated in
humans [34, 35]. Selecting patients at greatest risk of
bone metastases, by characterizing features of the pri-
mary tumour, could direct the optimal use of therapeu-
tics such as bisphosphonate and receptor activator of
nuclear factor-κB ligand (RANKL) inhibitors [36]. The
early detection of bone metastases, prior to radiological
detection or the onset of skeletal pain, by serum factors
or metabolomic profiles, could also potentially direct
treatment more judiciously than as a default adjuvant
therapy. In addition to the prediction of bone metasta-
ses and the selection of patients for therapies, there is
some evidence that certain lifestyle factors, particularly
vitamin D sufficiency and use of non-steroidal anti-
inflammatory drugs (NSAID) use, can influence a pa-
tient’s risk for developing metastatic disease following
their primary diagnosis, [37–40]. Understanding the
potential role and contribution of lifestyle factors to
the risk of developing bone metastases would inform
optimal lifestyle advice following primary breast cancer
diagnosis. Finally, characterising the specific breast cancer
cells or molecular signaling conditions that lead to overt
metastases could identify potential therapeutic targets for
tertiary prevention.
Program overview
The Breast Cancer to Bone Metastases (B2B) Research
Program is an on-going, dynamic, interdisciplinary re-
search program addressing multiple aspects of breast
cancer to bone metastases. Addressing these complex
questions is beyond the scope of a single project or in-
vestigator. Consequently, we assembled a core research
team with expertise ranging from basic science to popu-
lation health science to clinical care. Four core projects,
each investigating an important aspect of breast cancer
bone metastases, are based on the biologic samples and
data collected from a prospective cohort of breast cancer
patients, the B2B Cohort (Fig. 1). The B2B Research
Program was established to support four core projects
that examine the lifestyle, pathological, and biologic fac-
tors associated with these debilitating lesions. The over-
all B2B Research Program is approved by the provincial
research ethics board (Health Research Ethics Board of
Alberta, HREBA) and the University of Calgary institu-
tional ethics board (Conjoint Health Research Ethics
Board, CHREB).
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Core Project 1: Vitamin D, inflammation and bone
metastasis in breast cancer survivors
There is convincing evidence to support an inverse asso-
ciation between risk of breast cancer and both vitamin
D and calcium status (reviewed in [41]). Furthermore,
pre-clinical evidence, from animal models, suggests that
vitamin D may impede metastases to bone [42, 43].
However, the role of vitamin D in the development and
natural history of bone metastases, in humans, has not
yet been investigated. There are several plausible mecha-
nisms by which vitamin D may reduce risk or retard
development of bone metastases. Vitamin D exhibits pro-
differentiation and anti-proliferative properties [44, 45],
including the terminal differentiation of osteoclasts [46].
Accumulating evidence implicates sub-optimal vitamin D
status in the development of rheumatoid arthritis, diabetes
(types 1&2), multiple sclerosis, psoriasis, cardiovascular
disease, and cancer (reviewed in [47]). The etiology of
these chronic diseases all involve a suspected inflammatory
component compatible with the observed immunosup-
pressive and anti-inflammatory activity of 1,25-dihydroxy-
vitamin D, the active metabolite of Vitamin D, [48, 49].
The use of NSAID has recently been reported to re-
duce breast cancer recurrence [50] and improve survival
[51] and several of the genes identified in the bone
metastatic program, are associated with inflammatory
responses [31]. Therefore, chronic inflammation exacer-
bated by vitamin D inadequacy may potentiate the re-
cruitment of disseminated breast cancer cells to the
bone and the initiation of osteolytic metastatic bone
lesions.
During summer in North America, up to 90 % of vita-
min D is synthesized in the skin by ultraviolet B radiation
[UVB], with the remainder from food and supplements. In
the winter, especially for those living at latitudes above 42°
latitude (e.g., Boston, MA), diet and supplements are the
predominant sources of vitamin D. Therefore, both diet-
ary and supplemental intake and sun exposure must be
considered when assessing vitamin D status in a Canadian
population. An estimated 25–39 % of all Canadians are
vitamin D deficient and the prevalence of vitamin D defi-
ciency increases with age [52].
We will also measure 25-hydroxyvitamin D (25-OHD),
parathyroid hormone, calcium, creatinine, albumin, and
phosphate in serum, at baseline. Serum interleukin-1β (IL-
1B), Interleukin-6 (IL-6), interleukin-8 (IL-8), Interleukin-
11 (IL-11) and tumour necrosis factor-alpha (TNF-α) will
be measured as part of a 10-cytokine multiplex assay.
PTHrP expression will be quantified by automated immu-
nohistochemistry (IHC) (HistoRx®) in the primary tumour.
This project is approved by both the University of Calgary
institutional research ethics boards (CHREB).
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Fig. 1 B2B Research Program overview. Clinical data, questionnaire and interview responses, and biospecimens collected from the B2B Cohort are
used to support each of the four Core Projects
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Core Project 2: Primary breast tumour RNA expression and
bone metastasis
Previous studies have proposed primary tumour gene
expression patterns which appear to be candidate mo-
lecular pathways for migration to and successful growth
in the bone marrow [31, 32]. Some markers appear to be
particularly important in the process; these include:
CXCR4 (chemokine (C-X-C motif receptor 4), SDF1
(stromal cell-derived factor1, also known as CXCL12),
CTGF (connective tissue growth factor), FGF5 (fibro-
blast growth factor 5), MMP1 (matrix metallopeptidase
1), Il-11, PTHrP and osteopontin. These proteins have
acknowledged roles in cell recruitment, angiogenesis,
bone lysis, adhesion, migration [53–66] and are cur-
rently being evaluated as candidate therapeutic targets
for the prevention of metastasis. However, despite the
promising results in animal models, subsequent attempts
to identify a similarly informative signature in humans
have failed. It is likely that systemic factors interact with
tumour-specific factors to determine risk of bone metas-
tases [34].
This core project will investigate whether the ability
for breast cancer to metastasize to bone is an intrinsic
characteristic of the primary breast tumour or if sys-
temic factors are essential. Tumour protein marker ex-
pression will be evaluated on tissue microarrays (TMAs)
and quantified using fluorescence IHC and the HistoRx®
AQUAnalysis digital image analysis platform. Compart-
ment specific analysis of protein expression will be ac-
complished by the use of compartment-specific stains
(4′,6-diamidino-2-phenylindole (DAPI) for nuclei, pan-
cytokeratin for tumour cells and the tumour cytoplasm,
and vimentin for the non-malignant tumour-associated
stroma). In addition, RNA will be extracted from micro-
dissected tumour-enriched tissues from each tumour
and multiplexed target gene expression will be assayed
on a Luminex 200 platform using a custom designed
Affymetrix QuantiGene® Plex 2.0 assay. Systemic factors
will be measured in corresponding serum samples by
multiplexed Luminex protein assays. This project is ap-
proved by the University of Calgary institutional research
ethics board (CHREB).
Core Project 3: Metabolic markers of bone metastasis in
breast cancer survivors
Metabolism in cancer cells is clearly distinct from that
in normal cells. The shift in energy metabolism from
mitochondrial oxidative phosphorylation to an enhanced
reliance on glycolysis is commonly referred to as the
Warburg effect [67]. Other key metabolic pathways are
also commonly dysregulated, including the pentose phos-
phate shunt, the tricarboxylic acid cycle, lipid and
phospholipid turnover, choline metabolism, various redox
pathways and nucleotide biosynthesis [68]. Metabolic
profiles can be exploited through metabolomic approaches
as a potentially powerful method for cancer biomarker
discovery. The application of metabolic profiling towards
various cancers has been reviewed recently [68, 69] and
the use of large-scale metabolic analysis is gaining accept-
ance in multiple clinical settings [70]. To date, metabolic
profiling of serum or urine samples has been used, for ex-
ample, to distinguish between cancerous and benign
growth in pancreatic cancer patients [71], for staging pa-
tients suffering from colon cancer [72], for studying the
effectiveness of bladder cancer treatments [73], and for
distinguishing between ER+ and ER- breast cancer tu-
mours [74].
Recently, it has been suggested that ‘omics’ techniques
should be capable of predicting when metastasis to bone
in breast cancer patients will occur [75]. Indeed one
small-scale study already suggests that this type of pre-
diction may be feasible using a metabolomics approach
[76]. The B2B Research Program is based on a larger,
prospective study with pre-surgical baseline blood col-
lection and serial samples collected during extended
follow-up. We aim to derive a metabolic signature to
identify patients at highest risk of metastasis to bone,
potentially develop a test for early detection of bone
metastatic disease, and provide biologic insights into
both staging and transcriptional signatures and subtypes
within a single prospective cohort. This research brings
the prospect of a personalized treatment approach into
focus [77].
Our primary analytic platforms for metabolic profiling
are proton NMR spectroscopy and gas chromatography
time-of-flight mass spectrometry (GC-TOF-MS). These
are well-established methods that both provide quantita-
tive results for polar metabolites [68, 69, 71, 74]. The
metabolite profiles will subsequently be analyzed using
standard chemometric and multivariate statistical methods
[78] to determine a signature associated with bone me-
tastases. Serum samples are relatively non-invasive, pro-
vide an alternative to more invasive sampling techniques
[79, 80] and would be readily available for diagnostic and
prognostic studies in normal clinical settings for the pre-
diction and early detection of metastatic disease and
treatment response monitoring. This project is approved
by the institutional research ethics board (CHREB).
Core Project 4: Breast cancer mediated osteoclast
differentiation and bone lysis
The detection of breast cancer cells in bone marrow
aspirates from breast cancer patients, even those diag-
nosed at an early stage of disease, suggests that dissem-
ination of cancer cells is an early event in breast cancer
[15, 81]. However, only a subset of disseminated breast
cancer cells ever develop into overt metastases [82].
Many authors have suggested that only cells with stem-
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like properties can progress beyond micrometastases [83].
However, it is unclear whether these stem-like properties
are intrinsic or acquired at the metastatic site [84, 85]. Re-
cently the importance of epithelial-mesenchymal transi-
tion (EMT) and its reversion to an epithelial phenotype
for metastatic colonization has been highlighted [86, 87].
There have also been reports of EMT inducing stem-like
properties in cancer cells [88, 89] although the link is not
necessarily direct [86].
Breast cancer cells communicate with resident osteo-
clasts and osteoblasts in the bone marrow to establish
predominantly osteolytic lesions. The primary treatments
of bone metastases are bisphosphonates and RANKL
inhibitors (e.g. Denosumab®, monoclonal antibody to
RANKL). We will focus on the contribution of RANKL
signalling and RANKL-independent osteoclast activation
in the context of breast cancer bone metastases. The in-
teractions of cancer cells and cancer stem cells (tumour-
initiating cells) with osteoclasts in the initiation and
progression of osteolytic lesions and the signaling path-
ways that control these cells are areas of intense current
research [34, 90]. Determining which disseminated tumour
cells can initiate overt metastases [82] and identifying the
factors that control their interactions are essential to devel-
oping effective therapeutic and preventive strategies.
Putative tumour-initiating cells will be enriched from
primary breast tumour tissue, cultured and characterized
to examine the signalling pathway interactions within
the metastatic microenvironment. Specific candidate sig-
nalling pathways will be interrogated for their ability to
influence lytic osteoclast formation. Co-culture experi-
ments with breast cancer and bone marrow cells will fa-
cilitate interrogation of specific signalling pathways [91].
This project is approved by the Conjoint Health Re-
search Ethics Board (CHREB).
Understanding which subset of breast cancer cells had
the potential to establish overt metastases and which sig-
nalling pathways contribute to the progression of these le-
sions will support the early detection and risk assessment
for metastases and the development of targeted therapeu-




The population-based ascertainment of breast cancer
patients for the B2B Research Program was developed in
partnership with the Alberta Cancer Research Biobank
(ACRB) and the Alberta Cancer Registry (ACR). The
ACR is a province-wide cancer registry that has been
awarded a Gold Certification from the North American
Association of Central Cancer Registries since 1999, indi-
cating the highest quality of completeness, accuracy, and
timeliness of cancer reporting. Prior to the establishment
of the B2B Research Program, the ACRB focused predom-
inantly on the collection of fresh-frozen tumour tissue
from breast cancer patients in addition to a limited collec-
tion of largely post-surgical blood samples. The need to
recruit a population-based cohort and collect pre-surgical
blood samples, led to the development of the Comprehen-
sive Biospecimen Rapid Ascertainment (CoBRA) system
(Fig. 2). The CoBRA system is responsible for the ascer-
tainment of patients and their recruitment into the ACRB.
The ACRB is approved by both the institutional and pro-
vincial research ethics boards (HREBA and CHREB,
respectively).
The CoBRA system was designed to identify all newly
diagnosed breast cancer patients, within the Calgary
area, through seven multiply-redundant mechanisms.
The primary mechanism for patient identification is the
pathology reports pertaining to their diagnostic (pre-
surgical) fine needle and core biopsy. All biopsy reports
are submitted to the ACR; a copy of the report is also
submitted to dedicated ACRB personnel who are desig-
nated as affiliates of the ACR and bound by the code
of conduct and training required by all ACR personnel.
The additional six supplementary sources of patient as-
certainment are outlined in Table 1. Each new patient
is recorded in the CoBRA database and all correspond-
ence and patient contacts, pertaining to their informed
consent and biologic sample collection for the ACRB,
are managed within this system. Potential donors to
the ACRB are contacted only after their awareness of
their diagnosis has been confirmed. Written informed
consent is sought from each patient to donate a pre-
surgery (or pre-neoadjuvant therapy, if applicable)
blood sample and tumour tissue at surgery if sufficient
tissue is available without compromising pathologic as-
sessment or future clinical care. The informed consent
process for the ACRB consists of a Consent Informa-
tion Brochure and a separate consent form on which
patients select to participate or not and indicate their
willingness to be contacted regarding future research.
The comprehensive population-based ascertainment of
breast cancer patients commenced in February 2010. All
potentially eligible participants for the B2B Cohort are
selected from patients who agreed to participate in
ACRB. The CoBRA procedures will continue to ascer-
tain and recruit patients beyond the time frame of the
B2B Research Program, to support additional research
projects and biospecimen requests.
Study population
Patients with incident primary breast cancer are eligible
for recruitment into the B2B Cohort if they meet the fol-
lowing criteria as determined through the CoBRA data-
base: (1) histologically-confirmed stage I to stage IIIc
breast cancer diagnosed between 2010 and 2015; (2)
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residents of Calgary, Alberta and the surrounding areas;
(3) females ≥18 and ≤80 years at initial diagnosis; (4) able
to provide informed, written consent and complete ques-
tionnaires and an in-person interview in English; and, (5)
no previous cancer diagnosis with the exception of cer-
vical in-situ neoplasia (CIN) and non-melanoma skin can-
cer. Cohort participants must have donated a pre-surgical
blood sample to the ACRB (Fig. 3) and indicated willing-
ness to be contacted for future research. The contact de-
tails of eligible patients are then exported to the B2B
Research Program database for recruitment into the B2B
Cohort. The B2B Cohort is restricted to the Calgary area
because of the feasibility of processing blood samples col-
lected from community laboratories within 24 h.
Recruitment
The recruitment of patients into the B2B Cohort was har-
monized with recruitment for the Alberta Moving beyond
Breast cancER (AMBER) study [92] because the potential
participants are drawn from the same population of breast
cancer patients (Fig. 4). If a patient agrees to be contacted
regarding future research, contact details for all eligible
patients are imported into the AMBER & B2B Recruitment
Database. Patients are first invited to participate in the
AMBER study so that their exercise assessments can be
completed prior to the delivery of systemic therapy [92].
Patients are invited to participate in the B2B Cohort ap-
proximately 6–8 weeks post-surgery, and after potential
recruitment into the AMBER study. The B2B Research
Program Study Coordinator contacts eligible women by
telephone to explain the research program. If the potential
participant verbally agrees to receive the recruitment
package, their information is imported into the B2B
Tracking Database and they are mailed a letter of invita-
tion, consent information brochure, consent form and Pre
Interview Worksheets.
Fig. 2 B2B Research Program timeline. Recruitment for the B2B Cohort began in 2010, and steadily increased through successive operational
enhancements, key partnerships, and implementation of a centralized biospecimen ascertainment infrastructure
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Consenting participants complete baseline worksheets,
an in-person interview and post-interview questionnaires
within six months of an initial breast cancer diagnosis,
with follow-up assessment occurring at 24, 48 and
72-month intervals post-diagnosis. Passive follow-up,
through chart abstraction of medical records, will
occur at 10 years following the completion of the ac-
tive follow-up or for those who were lost to follow-
up but did not withdraw consent. We anticipate that
the recruitment of the baseline B2B Cohort will be
completed by August 2015; recruitment of the base-
line cohort of >600 participants will have taken a
total of 5.5 years. Analysis of data and biospecimens
will commence shortly afterwards.
Sample size
As a core infrastructure resource, the B2B Cohort sam-
ple size was not explicitly based on the power to address
a single hypothesis. However, to address our primary,
outcome–based hypotheses embedded within the core
projects, we will follow all cohort members (~600 pa-
tients) for a median of five years. Less than 60 % of
breast cancer recurrences are apparent within three
years of follow-up but ~80 % are evident after five years
of follow-up [3, 9, 10]. Within the 10-year time frame of
the B2B Research Program, we expect 70-80 women to
present with clinically evident bone metastases [3, 9, 10].
Using serum vitamin D concentrations as an example a
specific hypothesis to be tested, broad inter-quintile
ranges of serum [25-OHD] that are typical within North
American populations (Q1 < 14.9 ng/ml, Q5 > 35.3 ng/
ml [93]). Therefore, we anticipate that, for the vitamin D
and inflammation analyses, a 20 % difference in vitamin
D exposures and inflammatory status between women
with and without bone metastases will provide 80 %
power to detect a relative risk for bone metastases of 1.8
even with this modest sample size. We anticipate that
similar effect magnitudes will be observed in the other
core projects.
Data collection instruments
Pre-interview worksheets Each participant is mailed
pre-interview questionnaires including the Sun Exposure
Worksheets and Past Year Dietary Worksheets as part of
their recruitment package. Participants are asked to
complete these questionnaires and return them by mail.
The Sun Exposure Worksheets collect information on
residence, work history and vacation history for three
time periods: the 12 months prior to breast cancer diag-
nosis; the calendar year five years prior to breast cancer
diagnosis; and the calendar year 10 years prior to breast
cancer diagnosis. Although eligible participants must be
free of detectable distant metastases at diagnosis, breast
cancer cells can be disseminated early in tumour devel-
opment. Capturing exposure data for an extended pre-
diagnostic period, and during follow-up, ensures that
Table 1 Seven patient ascertainment and recruitment strategies to facilitate comprehensive population-based biospecimen accrual
and the potential for differential patient selection associated with each individual approach
Identification method Description Potential for selection bias
Alberta Cancer Registrya Pathological evidence of a positive cancer diagnosis provided
by the Alberta Cancer Registry.
Cancer registries may not capture 100 % of patient
populations and/or may not identify patients with
sufficient time for recruitment prior to treatment.
Direct Clinician Referral Collaborations with key high-volume clinicians including
surgeons and oncologists pro-actively introduce the ACRB
to patients during pre-treatment consultations
Not all clinicians are supportive or have the time
and/or resources to support recruitment initiatives.
Surgical Booking Request When a patient is diagnosed with a resectable cancer, a
surgical booking request is generated to secure a surgery
date and surgical suite.
Only includes patients scheduled for surgical
treatment for their cancer.
Pre-Admission Clinic The pre-admission clinic ensures that patients are prepared
for a scheduled operation or procedure.
Over-representation of patients with significant
co-morbidities and/or are considered at high risk of
complications during a medical procedure.
Day Surgery Unit (DSU) Patients are identified on the operating room slate and
encountered in the DSU just prior to their surgery on the
day of the operation.
Only includes patients treated for cancer with
surgery/excision.
Pre-treatment Patient Education Numerous programs are available to educate and inform
patients prior to treatment.
Patient education sessions are not mandatory;
only subsets of broader populations attend
these sessions.
Nurse Navigator Referral Oncology nurses are assigned to patients to help them
navigate the continuum of cancer care. They may
introduce patients to the ACRB and/or notify the ACRB that
a patient has entered their program [113].
Not all nurse navigators are prioritize research
recruitment and/or notify the ACRB of patients
entering their program.
aAdditional ethical considerations involving the patient’s awareness of diagnosis must be addressed prior to contacting a patient to obtain informed consent
for biobanking
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exposure can be estimated for the entire period that a
patient was at risk of disease dissemination.
The Past Year Dietary Worksheets collect data regard-
ing food intake and frequency in the 12 months prior to
breast cancer diagnosis, and was developed to assess in-
take of certain foods and supplements that have high
vitamin D and calcium content, consumed at a reason-
able frequency by female study participants in Alberta
[94]. The sun exposure, dietary, and supplement data
will be used to estimate levels of vitamin D during the
relevant exposure period.
In-person interview The completed pre-interview ques-
tionnaires are scanned using TELEform®, an optical
character recognition software program, then verified by
study staff for completeness before being exported into
the Blaise® computer-assisted interviewing draw 1soft-
ware program to pre-populate corresponding responses
in the B2B Baseline Interview. Furthermore, if the par-
ticipant has completed the AMBER Baseline Health
Questionnaire (BHQ), those verified responses are also
used to pre-populate corresponding responses in the B2B
Baseline Interview. By pre-populating the interview with
information provided by the participants in the pre-
interview questionnaires and the AMBER BHQ, we re-
duce participant interview burden and expedite the in-
person interview process.
One of the B2B Interviewers conducts the in-person
interview at a time and place convenient for the partici-
pant. The B2B Baseline Interview is typically an hour in
length, and collects information regarding pregnancy and
menstruation, menopausal status, hormone replacement
Alberta Cancer Registry 
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Fig. 3 Ascertainment recruitment, data and biospecimen collection and sharing scheme. Newly diagnosed cancer patients are identified through
the ACR, and are invited to donate biospecimen samples by the ACRB utilizing the CoBRA infrastructure. Clinical data and biospecimens are
stored by the ACRB, and contact information from eligible and consenting participants is sent to study coordinators of relevant research
programs. Subsequent blood samples and blood questionnaire data for routine study follow-up are collected by the ACRB and act as a shared
resource between the biorepository and research study team
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therapy, birth control and hormone contraceptive use,
personal health history/co-morbidity, medications (over-
the-counter and prescription), vitamins, minerals and
herbal supplements, mobility and physical activity, sun ex-
posure, diet history, family history of cancer, smoking
habits, alcohol consumption history, and demographic
information. Following the in-person interview, the par-
ticipant is provided with a Canadian Diet History Ques-
tionnaire II (DHQ II) and Past Year Total Physical
Activity Questionnaire (PAQ) [95], which is to be com-
pleted and returned to the study office by mail. If a B2B
participant has already completed the DHQII and PAQ as
part of the AMBER study, these responses are made avail-
able to the B2B Research Program to further reduce par-
ticipant burden.
Physical activity questionnaire The PAQ is adminis-
tered at four time points throughout the study: baseline
(post-interview), 24, 48 and 72-month follow-up. The
PAQ is a self-administered questionnaire in which partici-
pants report their occupational, transportation, household
and recreational/leisure physical activities over the previ-
ous 12 months. Participants report the number of hours
spent in each activity per week, allowing for analysis of
each individual type of activity as well as a summation of
all four categories of activities to determine the partici-
pant’s total amount of physical activity over the past year
[95]. These measures are expressed as metabolic equiva-
lents for each activity and are reported in total MET-
hours/week/year of activity [95].
Diet history questionnaire The DHQ II [96] is also ad-
ministered at four time-points during the study at base-
line (post-interview), 24, 48 and 72-month follow-up. It
is a self-administered food frequency questionnaire de-
veloped initially by the National Institute of Health and
then adapted for use in the Canadian population [96].
This FFQ is a comprehensive assessment of dietary in-
take in the previous 12 months that has 164 questions
about 134 food items and includes seasonal intake of a
variety of foods, the portion size and frequency of intake
for each food item. Responses from the DHQII provide
AMBER / B2B Eligible 















Fig. 4 B2B/AMBER participant recruitment. Eligible patients are identified by the ACRB through CoBRA processes, and the contact details of
consenting biospecimen donors are sent to a recruitment database shared by both the AMBER and B2B study coordinators. Patients are invited
to participate by each study, and if they agree, their information is then imported into the specific study database. Some information sharing
occurs between the AMBER and B2B study database, such as whether or not shared questionnaires have been completed
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comprehensive information on dietary habits, output of
nutrients and the amount foods and food groups con-
sumed. Additionally, the dose and frequency of vitamin
and mineral supplementation over the past year is also
obtained.
Biospecimen collection Each participant’s baseline blood
sample is collected as part of their ascertainment and up-
stream recruitment into the ACRB according to the
CoBRA procedures. Participants receive a blood requisi-
tion form and are asked to donate a blood sample at any
Calgary Laboratory Services location. The baseline col-
lection consists of a 60 ml of blood sample collected in six
6 ml Red Top (clot activator) vacutainers and four 6 ml
Lavender Top (EDTA) vacutainers. The vacutainers are
transported to a central processing laboratory and frac-
tionated by centrifugation to yield a total of 48 aliquots
comprised of 26 serum, 14 plasma, 4 buffy coat and 4 red
blood cells (400–500 μl per aliquot) in 1 ml Matrix® 2D-
barcoded tubes (Thermo Fisher Scientific Inc.). At the
time of blood collection, participants also complete a
short Blood Questionnaire that records information re-
garding their fasting status, recent smoking, medication,
supplement use, family history of cancer and menstrual
status.
Hematoxylin and eosin stained slides corresponding to
formalin-fixed paraffin embedded (FFPE) tissue blocks
are retrieved for all participants for whom tissue is avail-
able. Archived tissue blocks will be requested and re-
trieved according to the H&E slide pathology review; the
pathologist will mark the area of the block from which
triplicate 0.6 mm tissue cores should be collected for the
construction of TMAs. In addition to the collection of
tissue cores, 10 μm tissue scrolls will be collected for the
extraction of nucleic acids (DNA and RNA). The RNA
will be used for the transcript analysis in sub-project 2
and the DNA will be extracted at a later date for ancil-
lary projects potentially investigating mutational ana-
lyses. All blood and tissue samples are stored within the
ACRB.
Participant follow-up at 24, 48 or 72-months Add-
itional data and biospecimen collections occur at the
specified follow-up intervals of 24, 48 and 72-months
from the participant’s primary breast cancer diagnosis.
Each month, the Study Coordinator queries the B2B Re-
cruitment Database to generate a list of participants eli-
gible for follow-up. The Study Coordinator contacts
each participant by telephone to confirm their address
and willingness to continue their participation in the
B2B Research Program. If they agree, participants are
sent a follow-up package that includes a PAQ, DHQ II
and the appropriate Follow-Up Questionnaire (24, 48 or
72-month); these are self-administered questionnaires to
be completed by the participants and returned by mail
to the study office. The 24, 48 or 72-month Follow-Up
Questionnaires request information on: personal health
history, breast cancer progression (only at 24 month fol-
low up only), recurrence, contra-laterality and new pri-
mary diagnosis, medications (prescription and over the
counter), smoking habits, alcohol consumption, sun ex-
posure, dietary intake, mobility and physical activity and
anthropometric measurements.
Follow-up blood samples are also collected at 24, 48
and 72 months. Each Follow-Up Package contains a Re-
search Blood Requisition form and participants are asked
to donate a blood sample at any Calgary Lab Services
location. The follow-up blood collections consist of a
30 ml of blood sample collected using three 6 ml Red
Top (clot activator) vacutainers and two EDTA vacutai-
ners. Again, the vacutainers are transported to a central
processing laboratory, fractionated by centrifugation to
yield serum, plasma red blood cells and buffy coat and
stored in 32 aliquots of 400–500 μl in 1 ml Matrix® 2D-
barcoded tubes (Table 1).
Vital status check The vital status of each participant is
checked before each follow-up contact at 24, 48 and 72
months through a record linkage done by the Depart-
ment of Cancer Surveillance (Alberta Health Services).
Vital Statistics Alberta (VSA) provides information on
all deaths that occurred in the province to the ACR, on
request, with underlying cause of death provided by Sta-
tistics Canada to VSA. There is an average three-month
time lag between the actual death occurrence and
reporting to the ACR. Several mechanisms, such as re-
ciprocal agreements between other provinces and record
linkages with the Canadian Mortality Database, exist to
capture the deaths of participants who left the province
of Alberta after their diagnosis. These agreements and
processes ensure that vital status can be determined for
over 95 % of participants. Cause and date of death will
also be obtained from this source.
Medical record abstraction Medical record abstraction
will occur in the final year of the B2B Program operation
(commencing August 2018). Health Record Technicians
from the ACR will use direct data entry to a medical
record abstraction form to collect data from the medical
records (both paper and electronic charts) for all partici-
pants in the B2B Cohort. The medical record abstraction
form was developed from standardized forms used in
our past physical activity and breast cancer cohort study
conducted in Alberta [97, 98].
Baseline pathologic data, including clinical stage and
pathologic stage (according to American Joint Commit-
tee on Cancer criteria [99], tumor size, grade, histology,
estrogen receptor status, progesterone receptor status
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human epidermal growth factor receptor 2 status, type
and results of computerized tomography or positron
emission tomography scans, status of margins (with breast
conserving surgery), and pathology of lymph nodes (if sur-
gically sampled) are provided by the ACRB/CoBRA data-
base and verified during the medical record abstraction.
Abstracted variables will include the type of surgery, and
all treatment and follow-up care including data on chemo-
therapy, radiation therapy, and hormone therapy. Treat-
ment completion rates will be estimated for chemotherapy
and hormone therapy but not for radiation therapy since
few patients fail to complete radiation therapy. For
chemotherapy completion rate, we will estimate the aver-
age relative dose intensity (RDI) received for the originally
planned regimen based on standard formulae as we have
done in a previous RCT [100]. For hormone therapy, the
follow-up questionnaires ask participants to report if they
have stopped taking their prescribed hormone therapy at
any time before its intended completion and the reasons
for stopping.
Disease endpoints are defined according to the Stan-
dardized Definitions for Efficacy End Points in Adjuvant
Breast Cancer Trials [101]. Our primary endpoint of inter-
est is bone metastasis or a skeletal-related event according
to the definition in the NSABP 34 trial (http://clinical
trials.gov/show/NCT00009945). We will also examine
other composite disease endpoints as secondary endpoints
including overall survival, distant disease-free survival, dis-
tant relapse-free survival, and distant recurrence-free
interval. Finally, we will examine the single disease end-
points of death from breast cancer and death from non-
breast cancer. For participants who have left the province
and who are not known to be deceased, the date of leaving
Alberta will be used as the censoring time.
Discussion
Bone metastases are the most common site of breast
cancer metastasis and there are currently no curative
treatments available. Consequently, predicting the risk of
bone metastasis, identifying modifiable lifestyle strategies
to reduce those risks, developing methods for early de-
tection and understanding the fundamental biology and
potential therapeutic targets are of the highest priority.
The B2B Research Program seeks to address each of
these priorities via an integrated program of research
based on the population-based prospective B2B Cohort.
Each of the core projects (Fig. 1) focuses primarily on
one of these priorities; however, the integrated program
design and shared data and biospecimen resources
enables significant synergy between the projects and po-
tential for additional future hypothesis generation and
testing.
A population-based prospective cohort of incident
breast cancer patients offers the ideal study design to
address the priorities that we have identified. Framing
such research within existing randomised controlled trials
of treatment would be limited by the availability of biospe-
cimens and likely lack the external validity afforded by the
population-based ascertainment [102, 103]. Also, large
disease-free prospective cohorts, such as the Canadian
Partnership for Tomorrow Project [104], could not deliver
the necessary number of outcomes within a reasonable
period and are not currently configured to collect epide-
miologic data and biologic samples specifically during the
crucial peri-diagnostic period or conduct disease-specific
follow-up. Although previous studies have conducted
population-based recruitment of cancer patients in Al-
berta [94, 105], there was no existing mechanism to com-
prehensively identify, contact, obtain consent and track
breast cancer patients. Furthermore, the increasingly strin-
gent privacy requirements demanded the development of
a system that could accomplish the recruitment and bios-
pecimen collection targets whilst being sensitive to the
circumstances of the patients and complying with all rele-
vant privacy regulations. The establishment of the B2B
Research Program, the co-development of the CoBRA
database and procedures and the partnership with the
ACRB all contributed to the creation of the infrastructure
to facilitate the current and future population-based pro-
spective recruitment.
The collection of biospecimens is a critical component
of the B2B Research Program that required the develop-
ment of new procedures and the implementation of new
technology. Adopting the 1 ml Matrix® 2D-barcoded
tubes (Thermo Fisher Scientific Inc.) and the 2D bar-
code scanner (Thermo Fisher Scientific Inc.) enabled a
large number of relatively low-volume aliquots to be col-
lected and tracked for efficient inventory management
while avoiding excessive manual labelling and minimiz-
ing potential for human error. Two core projects within
the B2B Research Program are using serum samples to
investigate metabolomic and cytokine profiles associated
with the risk for bone metastases. Little has been pub-
lished on the impact of surgery [106–110] or systemic
therapy [111, 112] on serum biomarkers, but the existing
literature clearly demonstrates that there are significant
changes in blood-based markers in response to both sur-
gery and systemic therapy [106–110]. Consequently, the
collection of a pre-surgical blood sample is an eligibility
requirement for the B2B Cohort.
The detailed epidemiologic data collected on each par-
ticipant are collected using several data collection instru-
ments that have been adopted from previously published
research studies. The Pre-Interview Worksheets comprise
two short questionnaires developed for the OVarian can-
cer in ALberta (OVAL) Study [94] to improve the assess-
ment of overall vitamin D exposure as well as dietary
calcium intake. The computer-assisted baseline In-Person
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interview (Blaise®) was adapted from the interviews cre-
ated for the Alberta Endometrial Cancer Case-Control
Study [105] with modifications to address specific ques-
tions related to bone health and inflammation. The PAQ
that we use was developed to measure total physical activ-
ity in the previous year and has been tested for reliability
and validity [95]. The DHQ has also been specifically
modified to capture the food items available and con-
sumed in Canada [96]. By using existing instruments or
modifying those that had previously been used in similar
settings, we have minimized the development costs, taken
advantage of existing reliability measures and maximized
the comparability of our data with existing and future
studies using those instruments.
The B2B Research Program will address several critical
aspects of breast cancer bone metastases including pre-
diction, prevention, detection, and biology. Sub-clinical
vitamin D deficiency may be a prevalent, yet modifiable,
risk factor for breast cancer bone metastases. Optimal
vitamin D status may help prevent bone metastasis by a
fairly straightforward intervention through its reported
ability to attenuate inflammation and proliferation, while
promoting apoptosis and differentiation. The transcrip-
tional features of the primary tumour and systemic re-
sponse could provide a method to determine a patient’s
risk of bone metastases at diagnosis to direct appropriate
therapies or surveillance. Serum metabolomics offers the
potential for early detection of bone metastases. Further-
more, by combining these data with the epidemiologic
and clinical data, the impact of modifiable lifestyle fac-
tors on metabolites associated with bone metastases
might be determined. Finally, the in vitro and in vivo re-
search can dissect the biologic mechanisms and identify
potential therapeutic targets.
Lessons and limitations
Lessons learned during the set-up and early operation of
the B2B Research Program have greatly enhanced the as-
certainment and recruit of breast cancer patients in
Alberta, through the development of the CoBRA system
and refinement of study-specific processes. Translating
the comprehensive patient ascertainment into adequate
recruitment, and ultimately biospecimen collections, was
a significant challenge. However, continual development
of these processes and the supporting database has re-
sulted in sustainable recruitment, and biospecimen collec-
tion, from ~75 % of breast cancer patients in the Calgary,
Alberta area.
We originally proposed a tiered sampling mechanism
to enrich the B2B Cohort for stage III cancers who are
most likely to develop bone metastases. However, our
initial rate of recruitment was insufficient to implement
this strategy. The most significant obstacle was achieving
patient contact with sufficient time remaining to obtain
a pre-surgical blood sample. We introduced several
mechanisms to facilitate timely contact with patients
during clinic visits, through clinical care-related presen-
tations and during the peri-operative period whilst main-
taining the original correspondence-based procedures
(Fig. 2); these process enhancements improved our re-
cruitment rates and we anticipate the full baseline co-
hort recruitment to be completed by August 2015. In
addition, we have extended the follow-up program over
a longer duration (six years of follow-up instead of the
three year period originally proposed) to off-set the
lower event rates in early stage patients, to capture a
greater number of events overall and maximize statis-
tical power.
In 2013 we obtained approval from our institutional
ethics board to introduce email as a method of corres-
pondence between B2B Cohort members and our re-
search team. The pre-interview worksheet package has a
B2B Research Program email address with the B2B Re-
search Program Study Coordinator contact details. B2B
Cohort members are invited to correspond with B2B
Program personnel through this email address and are
asked to provide permission for research personnel to
contact them through their personal email address. E-
mail correspondence has been very popular and facili-
tates immediate engagement of new participants. It also
provides a mechanism to acknowledge receipt of study
materials, notify participants of their interviewer’s con-
tact details and to thank participants for their contribu-
tions. The use of e-mail has resulted in much more
efficient communication with participants with less
time spent telephoning, greater accessibility for both
participants and interviewers, and a greater number of
participants completing the interview portion of the
study.
In summary, the B2B Research Program is establish-
ing a population-based prospective cohort of breast
cancer patients in which we will conduct four initial
core research projects that will address key aspects of
bone metastasis in breast cancer survivors. The collec-
tion of pre-surgical blood samples and detailed epide-
miologic data, at baseline and follow-up, will provide a
unique and rich resource to address current and future
research. To our knowledge, no equivalent resources
are currently available. The biospecimen and data re-
sources established by the B2B Research Program will
also enable currently unanticipated important research
questions to be addressed in a timely manner. The ul-
timate goal of this research is to improve the prediction
of bone metastasis risk, identify modifiable lifestyle
strategies to reduce those risks, and improve our under-
standing of the fundamental biology and potential
therapeutic targets to reduce bone metastases in breast
cancer survivors.
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